Daisuke Kato, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Red-Cell Aplasia, Pure | 1 | 2019 | 27 | 0.660 |
Why?
|
| Erythema Infectiosum | 1 | 2019 | 15 | 0.660 |
Why?
|
| Parvoviridae Infections | 1 | 2019 | 36 | 0.660 |
Why?
|
| Parvovirus B19, Human | 1 | 2019 | 40 | 0.650 |
Why?
|
| Muscarinic Antagonists | 1 | 2017 | 135 | 0.550 |
Why?
|
| Acetanilides | 1 | 2017 | 169 | 0.520 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2017 | 115 | 0.510 |
Why?
|
| Vinblastine | 2 | 2010 | 488 | 0.390 |
Why?
|
| Thiazoles | 1 | 2017 | 1517 | 0.340 |
Why?
|
| Lymphocytes | 1 | 2017 | 2612 | 0.330 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2017 | 1405 | 0.310 |
Why?
|
| Monocytes | 1 | 2017 | 2570 | 0.300 |
Why?
|
| Medication Adherence | 1 | 2017 | 2176 | 0.250 |
Why?
|
| Japan | 5 | 2022 | 1378 | 0.230 |
Why?
|
| Antigens, Viral | 3 | 2022 | 988 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 5672 | 0.200 |
Why?
|
| Nutrition Assessment | 1 | 2024 | 728 | 0.180 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 131 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6484 | 0.140 |
Why?
|
| Trypsinogen | 1 | 2015 | 84 | 0.120 |
Why?
|
| Earthquakes | 1 | 2017 | 191 | 0.120 |
Why?
|
| Ethers, Cyclic | 1 | 2014 | 32 | 0.120 |
Why?
|
| Stereoisomerism | 3 | 2010 | 614 | 0.120 |
Why?
|
| Pancreatic Fistula | 1 | 2015 | 148 | 0.110 |
Why?
|
| Leukocyte Count | 1 | 2017 | 1596 | 0.110 |
Why?
|
| Macrolides | 1 | 2014 | 205 | 0.100 |
Why?
|
| Biological Products | 2 | 2014 | 914 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 954 | 0.100 |
Why?
|
| DNA, Viral | 1 | 2019 | 2202 | 0.100 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2015 | 509 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 2297 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 1303 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2015 | 622 | 0.090 |
Why?
|
| Transplantation Conditioning | 2 | 2009 | 1590 | 0.090 |
Why?
|
| Oxadiazoles | 1 | 2010 | 94 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 11742 | 0.090 |
Why?
|
| Communicable Diseases | 1 | 2017 | 875 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 4317 | 0.070 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 712 | 0.070 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2015 | 1277 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 3165 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2022 | 14665 | 0.070 |
Why?
|
| Retrospective Studies | 9 | 2024 | 80647 | 0.060 |
Why?
|
| Adult | 11 | 2024 | 221210 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2010 | 1791 | 0.060 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2005 | 305 | 0.060 |
Why?
|
| Amino Alcohols | 1 | 2005 | 19 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 1529 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 4251 | 0.060 |
Why?
|
| Diamines | 1 | 2005 | 60 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 2492 | 0.060 |
Why?
|
| Ketones | 1 | 2005 | 184 | 0.060 |
Why?
|
| Middle Aged | 12 | 2024 | 220921 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 9280 | 0.050 |
Why?
|
| Prognosis | 3 | 2024 | 29629 | 0.050 |
Why?
|
| Vascular Neoplasms | 1 | 2004 | 166 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2009 | 1347 | 0.050 |
Why?
|
| Amides | 1 | 2005 | 449 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 5305 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 457 | 0.050 |
Why?
|
| Glycine | 1 | 2005 | 663 | 0.050 |
Why?
|
| Graft vs Host Disease | 3 | 2009 | 3029 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 58984 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 520 | 0.040 |
Why?
|
| Humans | 16 | 2024 | 761596 | 0.040 |
Why?
|
| Aged | 9 | 2024 | 169310 | 0.040 |
Why?
|
| Female | 12 | 2024 | 392705 | 0.040 |
Why?
|
| Nasopharynx | 1 | 2022 | 401 | 0.040 |
Why?
|
| Male | 11 | 2024 | 360846 | 0.040 |
Why?
|
| Amino Acids | 1 | 2005 | 1718 | 0.040 |
Why?
|
| Catalysis | 2 | 2014 | 774 | 0.040 |
Why?
|
| Young Adult | 4 | 2021 | 59260 | 0.040 |
Why?
|
| Bacteremia | 1 | 2005 | 980 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2004 | 940 | 0.040 |
Why?
|
| Incidence | 4 | 2020 | 21355 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2022 | 937 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2022 | 1152 | 0.030 |
Why?
|
| Porifera | 1 | 2014 | 32 | 0.030 |
Why?
|
| Hematologic Diseases | 2 | 2005 | 496 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2015 | 3597 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 2231 | 0.020 |
Why?
|
| Adolescent | 4 | 2021 | 88326 | 0.020 |
Why?
|
| Alkylation | 1 | 2005 | 84 | 0.020 |
Why?
|
| Limbic Encephalitis | 1 | 2004 | 36 | 0.010 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2004 | 44 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 2004 | 139 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 2004 | 113 | 0.010 |
Why?
|
| Survival Analysis | 2 | 2009 | 10090 | 0.010 |
Why?
|
| HLA Antigens | 1 | 2009 | 1328 | 0.010 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 263 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2004 | 778 | 0.010 |
Why?
|
| Risk Factors | 3 | 2020 | 74213 | 0.010 |
Why?
|
| Graft Survival | 1 | 2009 | 3820 | 0.010 |
Why?
|
| Benzhydryl Compounds | 1 | 2005 | 916 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 2004 | 1474 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2009 | 1896 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 26202 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 54423 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 2693 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 36193 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 42232 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 39106 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 12059 | 0.010 |
Why?
|
| Child | 1 | 2017 | 80158 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2004 | 22176 | 0.000 |
Why?
|
| Animals | 1 | 2014 | 168475 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 13642 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2004 | 64685 | 0.000 |
Why?
|
| Neoplasms | 1 | 2005 | 22173 | 0.000 |
Why?
|